In the last trading session, 1.05 million shares of the Trevi Therapeutics Inc (NASDAQ:TRVI) were traded, and its beta was 0.47. Most recently the company’s share price was $6.61, and it changed around $0.21 or 3.28% from the last close, which brings the market valuation of the company to $639.07M. TRVI currently trades at a discount to its 52-week high of $7.39, offering almost -11.8% off that amount. The share price’s 52-week low was $2.30, which indicates that the current value has risen by an impressive 65.2% since then. We note from Trevi Therapeutics Inc’s average daily trading volume that its 10-day average is 1.8 million shares, with the 3-month average coming to 1.92 million.
Trevi Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended TRVI as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight.
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Instantly TRVI has showed a green trend with a performance of 3.28% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 6.98 on recent trading dayincreased the stock’s daily price by 5.3%. The company’s shares are currently up 60.44% year-to-date, but still up 0.76% over the last five days. On the other hand, Trevi Therapeutics Inc (NASDAQ:TRVI) is 53.36% up in the 30-day period. We can see from the shorts that 3.79 million shares have been sold at a short interest cover period of 4.54 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to decrease their stock price by -10.17% from its current value. Analyst projections state that TRVI is forecast to be at a low of $6 and a high of $6.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 27.09%. Trevi Therapeutics Inc earnings are expected to increase by -11.80% in 2025, but the outlook is negative -15.10% per year for the next five years.
TRVI Dividends
Trevi Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Mar-17.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.94% of Trevi Therapeutics Inc shares, and 86.27% of them are in the hands of institutional investors. The stock currently has a share float of 87.09%. Trevi Therapeutics Inc stock is held by 142.0 institutions, with NEA MANAGEMENT COMPANY, LLC being the largest institutional investor. By 2024-06-30, it held 11.2532% of the shares, which is about 11.37 million shares worth $33.88 million.
FRAZIER LIFE SCIENCES MANAGEMENT, L.P., with 7.305% or 7.38 million shares worth $22.0 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.24 shares worth $14.84 million, making up 2.32% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.6 shares worth around $10.59 million, which represents about 1.66% of the total shares outstanding.
